Last updated 6 days ago
A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
675 patients around the world
Available in United States, Argentina
Merck Sharp & Dohme LLC
3Research sites
675Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c.If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART).
- Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.Has a gastrointestinal disorder affecting absorption.Is HIV positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.Has received prior systemic anticancer therapy for their advanced or metastatic NSCLC.Has known additional malignancy that is progressing or has required active treatment within the past 3 years.Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.Has active autoimmune disease that has required systemic treatment in the past 2 years.History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.Has active infection requiring systemic therapy except those specified by protocol.Has history of stem cell/solid organ transplant.Has not adequately recovered from major surgery or has ongoing surgical complications.
Sites
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
StudyKANDLELIT-007
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07190248
